Suvorexant is filed at FDA by Merck Inc., for Sleep Disorder

A New Drug Application (NDA) for suvorexant, an investigational insomnia medicine, from Merck Inc., has been accepted for standard review by the FDA. Suvorexant will be evaluated by the Controlled Substance Staff of the FDA during NDA review. If approved by the FDA, suvorexant will become available after a schedule assessment and determination has been completed by the U.S. Drug Enforcement Administration, which routinely occurs after FDA approval. The company is continuing with plans to seek approval for suvorexant in other countries around the world.